MedTrace Logo

Assessing Medical Menstrual Regulation in the United States

NCT03972358 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 284

Last updated 2021-03-24

No results posted yet for this study

Summary

This study will assess the acceptability and use of medical menstrual regulation among women in the United States.

Conditions

  • Menstrual Regulation

Interventions

DRUG

Mifepristone

All participants will receive 200 mg mifepristone, to be taken orally on day 1.

DRUG

Misoprostol

All participants will receive 800 mcg misoprostol, to be taken buccally 24 hours after mifepristone (day 2)

Sponsors & Collaborators

  • Gynuity Health Projects

    lead OTHER

Principal Investigators

  • Wendy R Sheldon, PhD · Gynuity Health Projects

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-02-12
Primary Completion
2021-12-31
Completion
2021-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03972358 on ClinicalTrials.gov